Allergy Shots Success Rate: Per-Allergen Data and What the Research Shows

The overall success rate for allergy shots is approximately 50-80% of patients achieving clinically meaningful symptom improvement, based on AAAAI Practice Parameters and multiple systematic reviews. This range reflects the diversity of allergens, patient profiles, and treatment adherence patterns across studies. In the most rigorous evidence base — the Calderon Cochrane review of 51 randomized trials (2007) — the pooled symptom standardized mean difference was -0.73 versus placebo, comparable in effect size to intranasal corticosteroids. A Beijing HDM cohort study (Li et al., 2019) found that 57.4% were classified as high responders versus 42.6% low or non-responders at 3 years, suggesting the 'real-world' responder rate sits closer to the lower end of the published range.

Grass pollen and dust mite allergies have the strongest evidence and highest response rates. Grass SCIT has the largest trial base: the UK Immunotherapy Study Group (Frew et al., JACI 2006, n=410) reported 29% symptom reduction and 32% medication reduction at therapeutic dose. Dust mite SCIT has the highest single-allergen effect size: Calderon's Cochrane review (2010) found symptom SMD -0.95 and medication SMD -1.88 for HDM. Ragweed SCIT is well-established for allergic rhinitis but showed limited benefit for asthma in the foundational Creticos NEJM trial (1996). Cat SCIT produces approximately 60-72% symptom reduction at the 15 mcg Fel d 1 maintenance dose (Varney et al. 1997). At the weak end: cockroach SCIT failed its primary endpoint in the CRITICAL trial (Zoratti et al., JACI 2024), and dog SCIT has inconsistent evidence due to unstandardized extracts.

Treatment duration is the single most powerful predictor of allergy shot success. Lee et al. (Allergy Asthma Immunol Res 2018, n=304) found that treatment duration of at least 3 years predicted clinical remission with an odds ratio of 7.37 (p less than 0.001) — meaning patients who completed 3 years were over 7 times more likely to achieve durable remission than those who stopped earlier. Cumulative clinical remission was 76.6% at a mean follow-up of 4.9 years in that cohort. The EAACI Allergic Rhinoconjunctivitis Guideline explicitly states that at least 3 years is required for post-treatment efficacy to persist. Two-year courses are insufficient: the GRASS trial (Scadding et al., JAMA 2017) found neither 2 years of SCIT nor 2 years of SLIT produced sustained benefit 1 year after stopping.

Dust mite SCIT has the highest effect size of any single allergen in the published evidence base. Calderon's Cochrane review of perennial allergen immunotherapy (2010) found symptom SMD -0.95 (95% CI -1.77 to -0.14) and medication SMD -1.88 (95% CI -3.65 to -0.12) for house dust mite SCIT versus placebo. Dhami's EAACI asthma meta-analysis (Allergy 2017) found short-term symptom SMD -1.11 for HDM-driven asthma. Long-term data from Rodriguez-Plata (Immun Inflamm Dis 2023) reported 55% of patients asymptomatic at 10 years post-treatment. Lee et al. (2018) found 76.6% cumulative remission at mean 4.9 years in a dedicated HDM cohort. A 2021 network meta-analysis (Nelson, JACI Pract) found SCIT statistically outperformed SLIT drops for HDM symptom control — notable given that most single-allergen comparisons show equivalence.

Yes — the most rigorous modern cockroach SCIT trial produced negative results. The CRITICAL trial (Zoratti et al., J Allergy Clin Immunol 2024, NIAID Inner-City Asthma Consortium, n=57 cockroach-sensitized urban asthmatic children) found that mean nasal allergen challenge total nasal symptom scores did not differ between SCIT and placebo (P=0.63), even though cockroach-specific IgG4 rose approximately 200-fold — confirming immunological activity without clinical benefit. The earlier Wood 2014 ICAC pilot studies showed immunological activity from cockroach SCIT but provided no clinical efficacy data. AAAAI Practice Parameters acknowledge that cockroach AIT 'is not considered to have proven efficacy' for clinical outcomes. The only positive controlled trial for cockroach — Kang 1988 — had just 11 active and 2 control completers at 5 years and cannot be considered reliable evidence.

Several patient and allergen factors predict allergy shot success. Lee et al. (2018) found the strongest predictors of clinical remission in a 304-patient HDM cohort: treatment duration of at least 3 years (OR 7.37), high baseline HDM-specific IgE of at least 17.5 kU/L (OR 1.85), and milder baseline disease severity (severe AR was a negative predictor with OR 0.40). Calderon et al. (Allergy 2012) identified monosensitization, younger age, shorter allergy duration, and high baseline specific IgE as general predictors of response. Response at month 4 strongly predicts 24-month outcome (r=0.707), and month-12 response predicts 24-month success with an AUC of 0.860. These data suggest your allergist can often gauge your likelihood of long-term response within the first year of treatment.

For the best-studied allergens, direct and indirect meta-analyses generally show comparable efficacy between allergy shots (SCIT) and sublingual immunotherapy (SLIT). Nelson's network meta-analysis (JACI Pract 2015) found no significant difference between SCIT and SLIT tablets for grass: symptom SMD difference 0.0145 (not significant). Direct head-to-head double-blind trials (Khinchi et al., Allergy 2004 for birch; Eifan et al., 2010 for dust mites) found no statistically significant efficacy differences between routes, though sample sizes were small. The most important area of SCIT advantage is for polysensitized US patients needing custom multi-allergen mixes, where SLIT tablets (FDA-approved for single allergens only) cannot replicate the coverage — and at-home SCIT programs like Curex now deliver that custom multi-allergen shot route without weekly clinic visits. SLIT's clear advantage is in safety — zero documented fatalities versus approximately 1 per 2.5 million SCIT injections historically.